StockNews.com began coverage on shares of Senseonics (NYSE:SENS – Free Report) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock.
Separately, HC Wainwright reiterated a buy rating and issued a $2.00 price target on shares of Senseonics in a research note on Wednesday, August 14th.
Get Our Latest Analysis on Senseonics
Senseonics Price Performance
Senseonics (NYSE:SENS – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. Equities research analysts expect that Senseonics will post -0.13 EPS for the current year.
Institutional Trading of Senseonics
Large investors have recently bought and sold shares of the business. RPO LLC acquired a new stake in Senseonics during the 4th quarter worth about $37,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Senseonics in the 1st quarter valued at about $91,000. Virtu Financial LLC acquired a new stake in shares of Senseonics in the 1st quarter valued at about $162,000. Cubist Systematic Strategies LLC grew its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares during the period. 12.36% of the stock is currently owned by institutional investors and hedge funds.
About Senseonics
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
Featured Stories
- Five stocks we like better than Senseonics
- What to Know About Investing in Penny Stocks
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Stock Analyst Ratings and Canadian Analyst Ratings
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Invest in Insurance Companies: A GuideĀ
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.